Invasive Pneumococcal Disease After 2 Decades of Pneumococcal Conjugate Vaccine Use
Copyright © 2024 by the American Academy of Pediatrics..
OBJECTIVES: We sought to describe the evolving epidemiology of invasive pneumococcal disease (IPD) among children in Massachusetts, United States, over the last 2 decades during which sequential 7-valent pneumococcal conjugate vaccines (PCV7) and 13-valent PCVs (PCV13) were implemented.
METHODS: Cases of IPD in children aged <18 years were detected between 2002 and 2021 through an enhanced population-based, statewide surveillance system. Streptococcus pneumoniae isolates from normally sterile sites were serotyped and evaluated for antimicrobial susceptibility. IPD incidence rates and rate ratios with 95% confidence intervals (CIs) were calculated.
RESULTS: We identified 1347 IPD cases. Incidence of IPD in children aged <18 years declined 72% over 2 decades between 2002 and 2021 (incidence rate ratios 0.28, 95% CI 0.18-0.45). IPD rates continued to decline after replacement of PCV7 with PCV13 (incidence rate ratios 0.25, 95% CI 0.16-0.39, late PCV7 era [2010] versus late PCV13 era [2021]). During the coronavirus disease 2019 pandemic years, 2020 to 2021, the rate of IPD among children aged <18 years reached 1.6 per 100 000, the lowest incidence observed over the 20 years. In PCV13 era, approximately one-third of the IPD cases in children aged >5 years had at least 1 underlying condition (98, 30.3%). Serotypes 19A and 7F contributed 342 (48.9%) of all cases before implementation of PCV13 (2002-2010). Serotype 3 (31, 8.6%), and non-PCV13 serotypes 15B/C (39, 10.8%), 33F (29, 8.0%), 23B (21, 0.8%), and 35B (17, 4.7%) were responsible for 37.8% of cases in PCV13 era (2011-2021). Penicillin nonsusceptibility continued to decline (9.8% vs 5.3% in pre-/late PCV13 era, P = .003), however has become more common among non-PCV13 serotypes compared with vaccine serotypes (14.8% vs 1.4%, P < .001).
CONCLUSIONS: Robust ongoing surveillance networks are critical for identifying emerging serotypes and development of next-generation vaccine formulations.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:153 |
|---|---|
| Enthalten in: |
Pediatrics - 153(2024), 1 vom: 01. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yildirim, Inci [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Heptavalent Pneumococcal Conjugate Vaccine |
|---|
| Anmerkungen: |
Date Completed 02.01.2024 Date Revised 02.01.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1542/peds.2023-063039 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365786845 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365786845 | ||
| 003 | DE-627 | ||
| 005 | 20240108140850.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1542/peds.2023-063039 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1246.xml |
| 035 | |a (DE-627)NLM365786845 | ||
| 035 | |a (NLM)38087952 | ||
| 035 | |a (PII)e2023063039 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yildirim, Inci |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Invasive Pneumococcal Disease After 2 Decades of Pneumococcal Conjugate Vaccine Use |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.01.2024 | ||
| 500 | |a Date Revised 02.01.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 by the American Academy of Pediatrics. | ||
| 520 | |a OBJECTIVES: We sought to describe the evolving epidemiology of invasive pneumococcal disease (IPD) among children in Massachusetts, United States, over the last 2 decades during which sequential 7-valent pneumococcal conjugate vaccines (PCV7) and 13-valent PCVs (PCV13) were implemented | ||
| 520 | |a METHODS: Cases of IPD in children aged <18 years were detected between 2002 and 2021 through an enhanced population-based, statewide surveillance system. Streptococcus pneumoniae isolates from normally sterile sites were serotyped and evaluated for antimicrobial susceptibility. IPD incidence rates and rate ratios with 95% confidence intervals (CIs) were calculated | ||
| 520 | |a RESULTS: We identified 1347 IPD cases. Incidence of IPD in children aged <18 years declined 72% over 2 decades between 2002 and 2021 (incidence rate ratios 0.28, 95% CI 0.18-0.45). IPD rates continued to decline after replacement of PCV7 with PCV13 (incidence rate ratios 0.25, 95% CI 0.16-0.39, late PCV7 era [2010] versus late PCV13 era [2021]). During the coronavirus disease 2019 pandemic years, 2020 to 2021, the rate of IPD among children aged <18 years reached 1.6 per 100 000, the lowest incidence observed over the 20 years. In PCV13 era, approximately one-third of the IPD cases in children aged >5 years had at least 1 underlying condition (98, 30.3%). Serotypes 19A and 7F contributed 342 (48.9%) of all cases before implementation of PCV13 (2002-2010). Serotype 3 (31, 8.6%), and non-PCV13 serotypes 15B/C (39, 10.8%), 33F (29, 8.0%), 23B (21, 0.8%), and 35B (17, 4.7%) were responsible for 37.8% of cases in PCV13 era (2011-2021). Penicillin nonsusceptibility continued to decline (9.8% vs 5.3% in pre-/late PCV13 era, P = .003), however has become more common among non-PCV13 serotypes compared with vaccine serotypes (14.8% vs 1.4%, P < .001) | ||
| 520 | |a CONCLUSIONS: Robust ongoing surveillance networks are critical for identifying emerging serotypes and development of next-generation vaccine formulations | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Vaccines, Conjugate |2 NLM | |
| 650 | 7 | |a Heptavalent Pneumococcal Conjugate Vaccine |2 NLM | |
| 650 | 7 | |a Pneumococcal Vaccines |2 NLM | |
| 700 | 1 | |a Lapidot, Rotem |e verfasserin |4 aut | |
| 700 | 1 | |a Shaik-Dasthagirisaheb, Yazdani Basha |e verfasserin |4 aut | |
| 700 | 1 | |a Hinderstein, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Hanna |e verfasserin |4 aut | |
| 700 | 1 | |a Klevens, Monina |e verfasserin |4 aut | |
| 700 | 1 | |a Grant, Lindsay |e verfasserin |4 aut | |
| 700 | 1 | |a Arguedas Mohs, Adriano Gerardo |e verfasserin |4 aut | |
| 700 | 1 | |a Cane, Alejandro |e verfasserin |4 aut | |
| 700 | 1 | |a Madoff, Larry |e verfasserin |4 aut | |
| 700 | 1 | |a Johnson, Hillary |e verfasserin |4 aut | |
| 700 | 1 | |a Ivanof, Caryn |e verfasserin |4 aut | |
| 700 | 1 | |a Burns, Meagan |e verfasserin |4 aut | |
| 700 | 1 | |a Pelton, Stephen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pediatrics |d 1948 |g 153(2024), 1 vom: 01. Jan. |w (DE-627)NLM000021687 |x 1098-4275 |7 nnns |
| 773 | 1 | 8 | |g volume:153 |g year:2024 |g number:1 |g day:01 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1542/peds.2023-063039 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 153 |j 2024 |e 1 |b 01 |c 01 | ||